A Study to Evaluate Bleeding Patterns With Three Different Doses of DR-1031 Compared to Seasonale

PHASE2CompletedINTERVENTIONAL
Enrollment

567

Participants

Timeline

Start Date

October 31, 2006

Primary Completion Date

March 31, 2008

Study Completion Date

March 31, 2008

Conditions
Breakthrough Bleeding
Interventions
DRUG

DR-1031

Active therapy cycle of 84 days taking combination tablets containing ascending doses of ethinyl estradiol (EE) and 150 mcg levonorgestrel (LNG), followed by a 7-day withdrawal cycle of 10 mcg EE. The total extended cycle was 91 days and participants were to complete two extended cycles. Active therapy dosage of EE varied by treatment arm.

DRUG

Seasonale®

84 days of combination active tablets, each containing 30 mcg EE and 150 mcg LNG, followed by 7 days of placebo tablets for two consecutive 91-day cycles.

DRUG

Portia®

Portia® 28 consists of 21 pink active tablets, each containing 0.15 mg of levonorgestrel and 0.03 mg of ethinyl estradiol, and seven white inert tablets. Portia was taken as a pre-study run-in medication.

Trial Locations (50)

15206

Duramed Investigational Site, Pittsburgh

20737

Duramed Investigational Site, Riverdale

27103

Duramed Investigational Site, Winston-Salem

27511

Duramed Investigational Site, Cary

28562

Duramed Investigational Site, New Bern

29201

Duramed Investigational Site, Columbia

29425

Duramed Investigational Site, Charleston

29926

Duramed Investigational Site, Hilton Head Island

30005

Duramed Investigational Site, Alpharetta

30134

Duramed Investigational Site, Douglasville

31406

Duramed Investigational Site, Savannah

32207

Duramed Investigational Site, Jacksonville

32720

Duramed Investigational Site, DeLand

32935

Duramed Investigational Site, Melbourne

33186

Duramed Investigational Site, Miami

33401

Duramed Investigational Site, West Palm Beach

33407

Duramed Investigational Site, West Palm Beach

33607

Duramed Investigational Site, Tampa

35801

Duramed Investigational Site, Huntsville

38305

Duramed Investigational Site, Jackson

44122

Duramed Investigational Site, Cleveland

44124

Duramed Investigational Site, Mayfield Heights

46825

Duramed Investigational Site, Fort Wayne

64114

Duramed Investigational Site, Kansas City

67205

Duramed Investigational Site, Wichita

70006

Duramed Investigational Site, Metairie

70808

Duramed Investigational Site, Baton Rouge

71106

Duramed Investigational Site, Shreveport

72205

Duramed Investigational Site, Little Rock

75390

Duramed Investigational Site, Dallas

77024

Duramed Investigational Site, Houston

78229

Duramed Investigational Site, San Antonio

78737

Duramed Investigational Site, Austin

81001

Duramed Investigational Site, Pueblo

83642

Duramed Investigational Site, Meridian

83712

Duramed Investigational Site, Boise

84102

Duramed Investigational Site, Salt Lake City

85741

Duramed Investigational Site, Tucson

89030

Duramed Investigational Site, North Las Vegas

89109

Duramed Investigational Site, Las Vegas

89128

Duramed Investigational Site, Las Vegas

92083

Duramed Investigational Site, Vista

92108

Duramed Investigational Site, San Diego

92705

Duramed Investigational Site, Santa Ana

94102

Duramed Investigational Site, San Francisco

97401

Duramed Investigational Site, Eugene

97504

Duramed Investigational Site, Medford

06615

Duramed Investigational Site, Stratford

03756

Duramed Investigational Site, Lebanon

05495

Duramed Investigational Site, Williston

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Duramed Research

INDUSTRY

NCT00394771 - A Study to Evaluate Bleeding Patterns With Three Different Doses of DR-1031 Compared to Seasonale | Biotech Hunter | Biotech Hunter